In its updated guidance, the agency said it would only review a “small subset” of new emergency use authorization requests for COVID-19 tests that would likely fill an unmet need or have a significant benefit to the public.
“Taking into account the current status of manufacturing capacity and consumer access given the administration’s important investments in tests, for most new tests, shifting to traditional premarket review would best meet the public health needs at the current stage of the COVID-19 public health emergency,” Jeff Shuren, MD, director of the FDA’s Center for Devices and Radiological Health, said in a news release.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
